PMID- 29436872
OWN - NLM
STAT- MEDLINE
DCOM- 20190128
LR  - 20211204
IS  - 1744-8409 (Electronic)
IS  - 1744-666X (Linking)
VI  - 14
IP  - 3
DP  - 2018 Mar
TI  - Renal transplantation in anti-neutrophil cytoplasmic antibody vasculitis.
PG  - 235-240
LID - 10.1080/1744666X.2018.1440205 [doi]
AB  - Anti-neutrophil cytoplasmic antibody-associated vasculitis (AAV) has the 
      propensity to acquire a devastating disease course. Despite the advances in 
      therapeutics, a significant proportion of patients progress to end-stage renal 
      disease (ESRD). Renal transplantation is being increasingly employed in this 
      population, with gradual improvement in outcomes over the years, however, 
      recurrence of disease requires constant surveillance and is associated with graft 
      failure. Areas covered: A structured literature search in PubMed and Medline and 
      abstracts of international conferences was performed to identify cases and 
      cohorts of AAV patients who had undergone renal transplantation for ESRD. The 
      primary objective was to describe the long-term allograft and patient survival 
      and to reflect on current trends in transplantation in AAV and provide 
      recommendations for the phases of pre- and post-transplantation. Expert 
      commentary: Renal transplantation is the treatment of choice for AAV patients 
      with ESRD. The risk of relapse is low with modern immunosuppressive regimes 
      employing mycophenolate mofetil and tacrolimus. It is recommended that the 
      vasculitis be in clinical remission for 12 months prior to transplantation. 
      Although ANCA positivity is not a contraindication for renal transplantation, 
      these patients should be monitored closely for vasculitis relapse 
      post-transplant.
FAU - Geetha, D
AU  - Geetha D
AD  - a Division of Nephrology, Department of Medicine , Johns Hopkins University 
      School of Medicine , Baltimore , MD , USA.
FAU - Kant, S
AU  - Kant S
AD  - b Department of Medicine , University of Maryland Medical Center , Baltimore , MD 
      , USA.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20180222
PL  - England
TA  - Expert Rev Clin Immunol
JT  - Expert review of clinical immunology
JID - 101271248
RN  - 0 (Antibodies, Antineutrophil Cytoplasmic)
RN  - HU9DX48N0T (Mycophenolic Acid)
RN  - WM0HAQ4WNM (Tacrolimus)
SB  - IM
MH  - Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis/*immunology/mortality
MH  - Antibodies, Antineutrophil Cytoplasmic/*metabolism
MH  - Graft Rejection/*immunology/mortality
MH  - Humans
MH  - Immunosuppression Therapy
MH  - Kidney Failure, Chronic/immunology/mortality/*therapy
MH  - *Kidney Transplantation
MH  - Mycophenolic Acid/therapeutic use
MH  - Survival Analysis
MH  - Tacrolimus/therapeutic use
MH  - Treatment Outcome
OTO - NOTNLM
OT  - ANCA vasculitis
OT  - immunosuppression
OT  - outcomes
OT  - renal transplantation
OT  - vasculitis relapse
EDAT- 2018/02/14 06:00
MHDA- 2019/01/29 06:00
CRDT- 2018/02/14 06:00
PHST- 2018/02/14 06:00 [pubmed]
PHST- 2019/01/29 06:00 [medline]
PHST- 2018/02/14 06:00 [entrez]
AID - 10.1080/1744666X.2018.1440205 [doi]
PST - ppublish
SO  - Expert Rev Clin Immunol. 2018 Mar;14(3):235-240. doi: 
      10.1080/1744666X.2018.1440205. Epub 2018 Feb 22.